MH posted this the end of September in case you missed it.
Thursday, 09/29/16 05:57:03 PM
Re: cjgaddy post# 273899
Post # of 278792
Thanks for posting cj and much to be excited about in here.
As a reference point, likely known to many on this board. Dr. Wolchok is a direct and significant contributor for the development and commercialization of both Ipilimumab and Nivolumab. He and his lab were there with BMY early on from discovery, development and through market research and ultimately launch. He is one of the world's most renowned experts on Melanoma as a disease, and the mechanisms and pathways associated with it. To state the obvious - he is also still very closely tied with further development of the products and any potential combinations that may induce the next level of response beyond what PD1 and CTLA4 can achieve on their own.
He was involved in study 1 and is also a contributing author. His work is changing the course of disease in humanity and he will be credited with delivering tremendous benefits to Oncology and patients as more Melanoma patients get treated with Nivolumab and survive what otherwise would be a death sentence.
And he's working with Bavituximab.
He's also working with mice. He always had. Even when developing Ipi and Nivo.
Should give anyone who is objective about the current state of affairs in Peregrine a pause and an appreciation of what the possibilities are. These people are drawn to high-potential and work with the largest of the largest in industry. They feel it is worth their time to spend it on Bavi-inclusive combinations.
I'm taking that as a positive sign.
Thanks much for sharing and best,
MH
AI
Market Data 
Markets 
